The probability of NAMSA receiving an approval or no response within the thirty day period is high IMO!
Lets ask AI its opinion of the probability?
Probability of NAMSA Receiving IDE Approval Within 30 Days
Under U.S. FDA regulations, an IDE application is considered approved 30 calendar days after it is received by FDA, unless the FDA sends a written decision (approval, approval with conditions, or disapproval) earlier
Food and Drug Administration (.gov)
Food and Drug Administration (.gov)
. If no such decision is received within 30 days, the application is deemed approved by default.
For a significant risk device (such as the Hemostyp CelluSTAT gauze in this case), the sponsor must submit a complete IDE application, obtain IRB approvals at all study sites, and have signed investigator agreements?
If the submission is complete and meets all regulatory requirements, the 30-day default approval applies.
Key factors affecting the probability of approval within the 30-day period:
Completeness of the IDE submission: If all required data (device description, preclinical data, clinical protocol, risk analysis, manufacturing info, etc.) are included and meet FDA’s §812.20 requirements, the probability is high
FDA review workload: FDA’s review timelines can vary; in some cases, decisions are issued before 30 days, in others after. Historical data show that many complete IDEs are approved within the 30-day window, but incomplete or complex submissions can delay approval
No reply period: If FDA does not respond within 30 days, the IDE is approved by default, so the sponsor can proceed with IRB-approved enrollment
Food and Drug Administration (.gov)
Food and Drug Administration (.gov)
Bottom line:
If NAMSA has submitted a complete, compliant IDE application for a significant risk device, the probability of FDA approval within the 30-day no-reply period is very high — approaching 100% — because the default approval rule applies. The only way to avoid default approval is for FDA to issue a decision earlier, which is possible but not guaranteed.
Lets ask AI its opinion of the probability?
Probability of NAMSA Receiving IDE Approval Within 30 Days
Under U.S. FDA regulations, an IDE application is considered approved 30 calendar days after it is received by FDA, unless the FDA sends a written decision (approval, approval with conditions, or disapproval) earlier
Food and Drug Administration (.gov)
Food and Drug Administration (.gov)
. If no such decision is received within 30 days, the application is deemed approved by default.
For a significant risk device (such as the Hemostyp CelluSTAT gauze in this case), the sponsor must submit a complete IDE application, obtain IRB approvals at all study sites, and have signed investigator agreements?
If the submission is complete and meets all regulatory requirements, the 30-day default approval applies.
Key factors affecting the probability of approval within the 30-day period:
Completeness of the IDE submission: If all required data (device description, preclinical data, clinical protocol, risk analysis, manufacturing info, etc.) are included and meet FDA’s §812.20 requirements, the probability is high
FDA review workload: FDA’s review timelines can vary; in some cases, decisions are issued before 30 days, in others after. Historical data show that many complete IDEs are approved within the 30-day window, but incomplete or complex submissions can delay approval
No reply period: If FDA does not respond within 30 days, the IDE is approved by default, so the sponsor can proceed with IRB-approved enrollment
Food and Drug Administration (.gov)
Food and Drug Administration (.gov)
Bottom line:
If NAMSA has submitted a complete, compliant IDE application for a significant risk device, the probability of FDA approval within the 30-day no-reply period is very high — approaching 100% — because the default approval rule applies. The only way to avoid default approval is for FDA to issue a decision earlier, which is possible but not guaranteed.
